We're sharpening our digital tools!Introducing our sleek and powerful new video player for an even better viewing experience.Share your thoughts!

“SAFETY CONCERNS” HALT ANOTHER COVID DRUG TRIAL

Comments

With media attention focused on the COVID-19 “vaccine unicorn”, several alternative therapeutics currently in trial are getting little attention. Monoclonal antibody cocktails, touted by President Trump, claim to give COVID patients a boost of synthetic antibodies to help fight against the virus. Sounds great, but is there a catch? Eli Lilly has put their late-stage trial on hold due to a safety concern, leaving the public in the dark as to why.

POSTED: October 20, 2020